188 related articles for article (PubMed ID: 21990347)
1. Sympathetic control of bone mass regulated by osteopontin.
Nagao M; Feinstein TN; Ezura Y; Hayata T; Notomi T; Saita Y; Hanyu R; Hemmi H; Izu Y; Takeda S; Wang K; Rittling S; Nakamoto T; Kaneko K; Kurosawa H; Karsenty G; Denhardt DT; Vilardaga JP; Noda M
Proc Natl Acad Sci U S A; 2011 Oct; 108(43):17767-72. PubMed ID: 21990347
[TBL] [Abstract][Full Text] [Related]
2. Unloading induces osteoblastic cell suppression and osteoclastic cell activation to lead to bone loss via sympathetic nervous system.
Kondo H; Nifuji A; Takeda S; Ezura Y; Rittling SR; Denhardt DT; Nakashima K; Karsenty G; Noda M
J Biol Chem; 2005 Aug; 280(34):30192-200. PubMed ID: 15961387
[TBL] [Abstract][Full Text] [Related]
3. Deletion of OPN in BSP knockout mice does not correct bone hypomineralization but results in high bone turnover.
Bouleftour W; Juignet L; Verdière L; Machuca-Gayet I; Thomas M; Laroche N; Vanden-Bossche A; Farlay D; Thomas C; Gineyts E; Concordet JP; Renaud JB; Aubert D; Teixeira M; Peyruchaud O; Vico L; Lafage-Proust MH; Follet H; Malaval L
Bone; 2019 Mar; 120():411-422. PubMed ID: 30529011
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of osteoclastic bone resorption and suppression of osteoblastic bone formation in response to reduced mechanical stress do not occur in the absence of osteopontin.
Ishijima M; Rittling SR; Yamashita T; Tsuji K; Kurosawa H; Nifuji A; Denhardt DT; Noda M
J Exp Med; 2001 Feb; 193(3):399-404. PubMed ID: 11157060
[TBL] [Abstract][Full Text] [Related]
5. β2-Adrenergic receptor signaling in osteoblasts contributes to the catabolic effect of glucocorticoids on bone.
Ma Y; Nyman JS; Tao H; Moss HH; Yang X; Elefteriou F
Endocrinology; 2011 Apr; 152(4):1412-22. PubMed ID: 21266510
[TBL] [Abstract][Full Text] [Related]
6. Genetic determination of the cellular basis of the sympathetic regulation of bone mass accrual.
Kajimura D; Hinoi E; Ferron M; Kode A; Riley KJ; Zhou B; Guo XE; Karsenty G
J Exp Med; 2011 Apr; 208(4):841-51. PubMed ID: 21444660
[TBL] [Abstract][Full Text] [Related]
7. PTH regulates β2-adrenergic receptor expression in osteoblast-like MC3T3-E1 cells.
Moriya S; Hayata T; Notomi T; Aryal S; Nakamaoto T; Izu Y; Kawasaki M; Yamada T; Shirakawa J; Kaneko K; Ezura Y; Noda M
J Cell Biochem; 2015 Jan; 116(1):142-8. PubMed ID: 25164990
[TBL] [Abstract][Full Text] [Related]
8. Osteopontin expression in co-cultures of human squamous cell carcinoma-derived cells and osteoblastic cells and its effects on the neoplastic cell phenotype and osteoclastic activation.
Teixeira LN; de Castro Raucci LM; Alonso GC; Coletta RD; Rosa AL; de Oliveira PT
Tumour Biol; 2016 Sep; 37(9):12371-12385. PubMed ID: 27312487
[TBL] [Abstract][Full Text] [Related]
9. Thyrotoxicosis Involves β2-Adrenoceptor Signaling to Negatively Affect Microarchitecture and Biomechanical Properties of the Femur.
Neofiti-Papi B; Albuquerque RP; Miranda-Rodrigues M; Gonçalves NJN; Jorgetti V; Brum PC; Ferreira JCB; Gouveia CHA
Thyroid; 2019 Aug; 29(8):1060-1072. PubMed ID: 31264512
[No Abstract] [Full Text] [Related]
10. Genetic and epigenetic regulation of osteopontin by cyclic adenosine 3' 5'-monophosphate in osteoblasts.
Miki H; Okito A; Akiyama M; Ono T; Tachikawa N; Nakahama KI
Gene; 2020 Dec; 763():145059. PubMed ID: 32858177
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin is required for unloading-induced osteoclast recruitment and modulation of RANKL expression during tooth drift-associated bone remodeling, but not for super-eruption.
Walker CG; Dangaria S; Ito Y; Luan X; Diekwisch TG
Bone; 2010 Dec; 47(6):1020-9. PubMed ID: 20828639
[TBL] [Abstract][Full Text] [Related]
12. Deletion of Osteopontin Enhances β₂-Adrenergic Receptor-Dependent Anti-Fibrotic Signaling in Cardiomyocytes.
Pollard CM; Desimine VL; Wertz SL; Perez A; Parker BM; Maning J; McCrink KA; Shehadeh LA; Lymperopoulos A
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30897705
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption.
Togari A; Arai M
J Pharmacol Sci; 2008 Apr; 106(4):542-6. PubMed ID: 18431037
[TBL] [Abstract][Full Text] [Related]
14. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells.
Togari A
Microsc Res Tech; 2002 Jul; 58(2):77-84. PubMed ID: 12203706
[TBL] [Abstract][Full Text] [Related]
15. Regulation of the osteopontin gene by the orphan nuclear receptor NURR1 in osteoblasts.
Lammi J; Huppunen J; Aarnisalo P
Mol Endocrinol; 2004 Jun; 18(6):1546-57. PubMed ID: 14988426
[TBL] [Abstract][Full Text] [Related]
16. Dose effects of butoxamine, a selective β2-adrenoceptor antagonist, on bone metabolism in spontaneously hypertensive rat.
Arai M; Sato T; Takeuchi S; Goto S; Togari A
Eur J Pharmacol; 2013 Feb; 701(1-3):7-13. PubMed ID: 23321373
[TBL] [Abstract][Full Text] [Related]
17. Osteopontin Promotes Oncostatin M Production in Human Osteoblasts: Implication of Rheumatoid Arthritis Therapy.
Su CM; Chiang YC; Huang CY; Hsu CJ; Fong YC; Tang CH
J Immunol; 2015 Oct; 195(7):3355-64. PubMed ID: 26304992
[TBL] [Abstract][Full Text] [Related]
18. Osteoclasts secrete osteopontin into resorption lacunae during bone resorption.
Luukkonen J; Hilli M; Nakamura M; Ritamo I; Valmu L; Kauppinen K; Tuukkanen J; Lehenkari P
Histochem Cell Biol; 2019 Jun; 151(6):475-487. PubMed ID: 30637455
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin in Bone Metabolism and Bone Diseases.
Si J; Wang C; Zhang D; Wang B; Zhou Y
Med Sci Monit; 2020 Jan; 26():e919159. PubMed ID: 31996665
[TBL] [Abstract][Full Text] [Related]
20. Regulation of osteopontin expression in osteoblasts.
Sodek J; Chen J; Nagata T; Kasugai S; Todescan R; Li IW; Kim RH
Ann N Y Acad Sci; 1995 Apr; 760():223-41. PubMed ID: 7785896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
